Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for DiverticulosisJuly 16, 2020

Emmaus Life Sciences, Inc. is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of HealthJune 29, 2020

Emmaus Life Sciences, Inc. announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel.

National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life SciencesJune 25, 2020

Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications

Emmaus Life Sciences Provides Operational UpdatesJune 02, 2020

Emmaus Life Sciences, Inc., provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020.

APCER Report Confirms Endari ® SafetyApril 27, 2020

Emmaus announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.